Denying the elderly important advances in the treatment of lung cancer on prejudice alone is no longer justified. The fit elderly person with adequate organ function should be offered similar treatment to younger patients. Other elderly patients should ideally be included in randomised trials to provide an evidence base.
No takes yet. Share an insight, caveat, or question.
Richard Booton (2003) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: